IMI - Call 15: Antimicrobial resistance networks

IMI-2 (Innovative medicines initiative) - has launched its Antimicrobial Resistance (AMR) Accelerator programme with calls for 2 networks. Deadline is October 24th, 2018.

Capability Building Network (CBN) to accelerate and validate scientific discoveries

The CBN will work to address the innovation gap in the AMR space by enabling pre-competitive research in the treatment and prevention of multidrug resistant infections. The aims are to

  • create an operational group to support the delivery of projects
  • conduct pre-competitive research aimed to (i) provide learnings derived from shared vaccine and/or antibacterial clinical trial data, and (ii) improve understanding of variability and translatability of animal models of bacterial infection.

Link to call

Available funding: 8 M€, indicative duration 72 months.

A webinar on the topic was held July 16th. Click to see presentations, recording and list of participants.

 

Tuberculosis drug development network (TBDDN) to accelerate and validate scientific discoveries and advance the RnD pipeline of new and innovative agents

The main objective of the TBDDN network is to provide a unique platform where discovery, development, and clinical trial readouts will occur allowing maximal engagement across groups in the TB field.

Link to call

Available funding: 89,8 M€, indicative duration 72 months.

A webinar on the topic was held July 16th. Click to see presentations, recording and list of participants.

 

Deadline

A two-stage application is foreseen. Academic/SME consortia will apply in stage 1. The winning academic/SME consortium and the industry consortium will write a joint, final application to be subjected to a go/no go decision. The stage 1 deadline is October 24th, 2018.
 

IMI webpage

 

 

Published June 29, 2018 2:43 PM - Last modified Aug. 2, 2018 11:14 AM